Medpace (NASDAQ:MEDP) Issues FY 2025 Earnings Guidance

Key Points

• Medpace updated its FY 2025 earnings guidance, projecting earnings per share (EPS) between $14.600 and $14.860, surpassing the consensus estimate of $14.230.
• The company set revenue guidance at $2.5 billion, which aligns with analysts' expectations for the same period.
• Medpace's stock currently has a consensus rating of "Reduce" with an average target price of $430.60, as analysts adjust their ratings amidst various price target changes.

Medpace (NASDAQ:MEDP - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 14.600-14.860 for the period, compared to the consensus estimate of 14.230. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Robert W. Baird increased their price objective on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. TD Cowen reissued a "sell" rating and issued a $366.00 price objective (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Cowen downgraded Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Rothschild & Co Redburn downgraded Medpace from a "buy" rating to a "neutral" rating and raised their target price for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Finally, UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and raised their target price for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $430.60.

Medpace Stock Up 0.2%

Shares of MEDP traded up $1.10 during midday trading on Wednesday, reaching $546.74. The company had a trading volume of 769,365 shares, compared to its average volume of 427,028. Medpace has a 1-year low of $250.05 and a 1-year high of $554.14. The stock has a market cap of $15.36 billion, a PE ratio of 40.65, a price-to-earnings-growth ratio of 3.38 and a beta of 1.40. The firm has a 50 day simple moving average of $495.85 and a 200-day simple moving average of $385.79.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.49 by $0.37. Medpace had a return on equity of 67.66% and a net margin of 18.74%. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts anticipate that Medpace will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Cornelius P. Mccarthy III sold 1,662 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director directly owned 10,197 shares of the company's stock, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the firm's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company's stock, valued at $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Medpace

Several institutional investors have recently bought and sold shares of the company. Wasatch Advisors LP boosted its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock valued at $296,853,000 after buying an additional 116,354 shares during the period. AQR Capital Management LLC boosted its stake in shares of Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company's stock valued at $193,269,000 after buying an additional 81,637 shares during the period. Bank of America Corp DE boosted its stake in shares of Medpace by 4.6% in the 2nd quarter. Bank of America Corp DE now owns 189,964 shares of the company's stock valued at $59,622,000 after buying an additional 8,342 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock valued at $24,929,000 after buying an additional 3,010 shares during the period. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Medpace by 958.1% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 48,356 shares of the company's stock valued at $15,177,000 after buying an additional 43,786 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.